Sorry to say but that’s clearly not going to happen. We are in the middle of 2020 - its June in just over a week.
There’s a lot of us shareholders been here for a while and there’s a reason why we are conflicted with regards to the company - myself included because although the technology looks good, the company has a history of unfulfilled dates and targets. Bob’s comment re middle of 2020 is just another.
The company hasn’t even decided whether they are going to run the trial in Australia or the US or both. Then once that decision is made you need to seek the regulatory approvals, patient recruitment etc. Here in Australia at any one point in time the sample size of those affected by HER2 breast cancer is not that big so it will be almost impossible IMO to conduct the trial in Australia which is why I’m skeptical about yesterdays announcement - in fact I saw it as basically meaningless and was amazed (pleasantly so) as to why the stock traded and reacted to it like it did.
This is a link to a post I made only a month ago in the midst of the rights issue debacle. And for the record the management and Bob having no shares is an issue because no one person with significant “skin in the game” would ever have conducted a rights issue at 1 cent let alone with a 1:1 new series of option, certainly not in the week of “peak Covid hysteria with regards to equity markets and then taken all the oversubscriptions (to non shareholders because we all got scaled back applying for overs) by virtue of a “follow up placement” only to have half of it blocked by the regulators.They gave the company away - it never had to be priced at that level and if you believe Bob the extra $500k odd (that had to be cancelled) was needed to get through to clinical trials so that in itself implies a whole in the budget.
https://hotcopper.com.au/posts/44278919/singleTed
